Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral–Experienced Patients With Hepatitis C. (10th March 2017)

• Record Type: Journal Article
• Authors: Hézode, Christophe; Fourati, Slim; Chevaliez, Stéphane; Scoazec, Giovanna; Soulier, Alexandre; Varaut, Anne; François, Murielle; Ruiz, Isaac; Roudot-Thoraval, Françoise; Mallat, Ariane; Pawlotsky, Jean-Michel
• Is Part Of: Clinical infectious diseases. Volume 64:Number 11(2017)
• Page Start: 1615
• Page End: 1618
• Publication Date: 2017-03-10
• Subjects: chronic hepatitis C -- retreatment -- sustained virological response -- resistance -- resistance-associated substitutions.; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/cix214
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: We assessed the broadly used, off-label combination of sofosbuvir, daclatasvir, simeprevir, and ribavirin in direct-acting antiviral–experienced patients, as recommended in current guidelines despite scarce data. After 24 weeks' treatment, sustained virological response 12 weeks after the end of treatment was achieved in 6 patients (60%). Two cirrhotic patients relapsed and 2 discontinued treatment due to serious adverse events.